A Phase II trial of the ACC-011 compound for Alzheimer's disease being developed by Elan Corp. plc and Wyeth Pharmaceuticals has been suspended due to a skin lesion observed in a single patient. (BioWorld Today)

The limited effects of leading treatments for Alzheimer's disease has helped spur a growing field of research into new drug targets that could slow the course of the disease. (BioWorld Financial Watch)

Nearly a month after taking steps to streamline the company, PDL BioPharma Inc. said it plans to spin off its biotechnology assets into a separate publicly traded firm. (BioWorld Today)

Keryx BioPharmaceuticals Inc. said it plans to restructure the company, slashing half its workforce, closing three facilities, and delaying or ending several research programs, in the wake of its failed investigative drug Sulonex. (BioWorld Today)